Autonomix Medical Shuffles Leadership, Appoints New CFO

TL;DR

New CFO and board changes at Autonomix Medical, effective immediately.

AI Summary

Autonomix Medical, Inc. announced on June 17, 2024, the departure of its Chief Financial Officer, Michael L. Collins. The company also elected new directors and appointed new officers, including the appointment of David L. Smith as Chief Financial Officer. These changes are effective immediately.

Why It Matters

Significant changes in key financial and directorial roles can impact investor confidence and the company's strategic direction.

Risk Assessment

Risk Level: medium — Leadership changes, especially in financial roles, can introduce uncertainty regarding future strategy and financial management.

Key Players & Entities

• Autonomix Medical, Inc. (company) — Registrant
• Michael L. Collins (person) — Departing Chief Financial Officer
• David L. Smith (person) — Appointed Chief Financial Officer
• June 17, 2024 (date) — Effective date of changes

FAQ

Key Financial Figures

• $0.001 — h Registered Common Stock , par value $0.001 per share AMIX The Nasdaq Stock Mark
• $450,000 — es for an initial annual base salary of $450,000 (subject to an annual review and increa
• $1,000,000 — etion of this offering will be equal to $1,000,000 divided by the Black-Scholes value per
• $150,000 — es for an initial annual base salary of $150,000 (subject to an annual review and increa

Filing Documents

• amix20240615_8k.htm (8-K) — 38KB
• ex_688939.htm (EX-10.1) — 68KB
• ex_688940.htm (EX-10.2) — 67KB
• ex_689006.htm (EX-99.1) — 16KB
• hauser.jpg (GRAPHIC) — 3KB
• logo01.jpg (GRAPHIC) — 3KB
• logo.jpg (GRAPHIC) — 2KB
• 0001437749-24-020534.txt ( ) — 378KB
• amix-20240617.xsd (EX-101.SCH) — 3KB
• amix-20240617_def.xml (EX-101.DEF) — 12KB
• amix-20240617_lab.xml (EX-101.LAB) — 15KB
• amix-20240617_pre.xml (EX-101.PRE) — 12KB
• amix20240615_8k_htm.xml (XML) — 3KB

02. Unregistered Sales of Equity Securities

Item 3.02. Unregistered Sales of Equity Securities The information contained below in Item 5.02 related to the Inducement Options and the shares of common stock issuable thereunder is hereby incorporated by reference into this Item 3.02. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Brad Hauser Employment Agreement On June 17, 2024, Autonomix Medical, Inc. (the "Company") entered into an employment agreement with Brad Hauser pursuant to which Mr. Hauser agreed to serve as the Company's chief executive officer and president for an initial three-year period, which may be extended on a year-to-year basis. Mr. Hauser's agreement provides for an initial annual base salary of $450,000 (subject to an annual review and increase at the discretion of the Company's Compensation Committee) and a target annual bonus of 60% of his base salary. Pursuant to the agreement, Mr. Hauser was granted a ten-year option (the "Inducement Options") to purchase 900,000 shares of common stock at an exercise price equal to the closing price of the Company's common stock on the date of the employment agreement. The option vests in four equal annual installments (or 225,000 shares each installment) on each of the succeeding four anniversary dates of the execution of the employment agreement, provided Mr. Hauser is employed by the Company on each vesting date. In the event of a "change of control" or the termination of the agreement by the Company without "cause" or by Mr. Hauser for "good reason," all of the unvested options shall immediately vest. The Inducement Options are being granted outside of the Company's 2023 Stock Plan as an inducement material to Mr. Hauser's entering into employment with the Company in accordance with Nasdaq Stock Market Listing Rule 5635(c)(4). Commencing with the year ending March 31, 2025, Mr. Hauser will be eligible to receive annual option grants

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure On June 17, 2024, the Company issued a press release which announced Brad Hauser as the Company's new Chief Executive Officer and Lori Bisson, the Company's former Chief Executive Officer, as Vice-Chairman and Strategic Adviser to the Chief Executive Officer. A copy of the press release is attached to this report as Exhibit 99.1 and is incorporated by reference herein. The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be "filed" for the purpose of the Securities Exchange Act of 1934, as amended ("Exchange Act"), nor shall it be incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended ("Securities Act"), unless specifically identified therein as being incorporated by reference.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits (d) Exhibits Exhibit No. Exhibit 10.1 Employment Agreement between Brad Hauser and Autonomix Medical, Inc. dated June 17, 2024. 10.2 Employment Agreement between Lori Bisson and Autonomix Medical, Inc. dated June 17, 2024. 99.1 Press Release dated June 17, 2024. 104 Cover page Interactive Data File (embedded within the Inline XBRL document) Signature Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AUTONOMIX MEDICAL, INC. By: /s/ Trent Smith Trent Smith Chief Financial Officer Dated: June 17, 2024

View Full Filing

View this 8-K filing on SEC EDGAR